【国泰海通医药】春节期间创新药领域重点新闻梳理-海外公司 1）2/12 公司自2019年起任职的CEO PaulHudson不再续聘，前默沙东CEO BelénGarijo上任（#过去3年赛诺菲临床失 败多管线青黄不接）； 2）2/17 赛诺菲&TEVA更新了共同开发的TL1A单抗duvakitug IIb期更长期随访的数据，其中44周时接受900mg药物维 持治疗的UC患者临床缓解率达到58%（较安 【国泰海通医药】春节期间创新药领域重点新闻梳理-海外公司 赛诺菲： 1）2/12 公司自2019年起任职的CEO PaulHudson不再续聘，前默沙东CEO BelénGarijo上任（#过去3年赛诺菲临床失 败多管线青黄不接）； 2）2/17 赛诺菲&TEVA更新了共同开发的TL1A单抗duvakitug IIb期更长期随访的数据，其中44周时接受900mg药物维 持治疗的UC患者临床缓解率达到58%（较安慰剂提高27%），CD患者的内镜应答率达到55%（较安慰剂提高 35%），相比16周均有提高，数据亮眼； 阿斯利康： 1）2/20 FDA批准阿斯利康阿克替尼联合维奈托克全口服、固定疗程方案针对一线CLL ...

Sanofi (NASDAQ:SNY) is among the 7 Oversold Pharma Stocks to Buy Now. Sanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA Sanofi (NASDAQ:SNY) is one of the most oversold stocks. TheFly reported that on February 20, SNY’s price target was lowered at Citi by EUR 5. On the other hand, earlier on February 12, BofA reduced its price target for SNY from EUR 102 to EUR 92 and downgraded the stock from Buy to Neutral. Following the announcement that Belén Garijo, the former CEO of Merck KGaA, wi ...

机构观点 招银国际报告指出，制药与生物技术客户需求呈现反弹，生物技术融资恢复可能在未来6-12个月转化为 订单增量，这将成为赛默飞世尔收入增长的潜在驱动因素。 以上内容基于公开资料整理，不构成投资建议。 股票近期走势 近一周股价呈现波动，截至2026年2月20日收盘价为510.93美元，较2月17日上涨1.21%，区间振幅达 3.44%。成交额方面，2月20日成交额为6.96亿美元，较前一日减少33.06%；2月19日成交额为9.08亿美 元；2月18日成交额为13.56亿美元；2月17日成交额为18.97亿美元。同期换手率从1.00%降至0.36%，显 示交易活跃度有所回落。 来源：经济观察网 经济观察网 赛默飞世尔于2026年2月16日发布2026年业绩指引，预计收入同比增长3.9%至5.9%，调整后 每股收益增长5.9%至8.4%。公司近期完成对Solventum过滤与分离业务及赛诺菲新泽西州无菌灌装设施 的收购，并宣布拟以89亿美元收购临床数据服务商Clario，以加强生物生产与药品本土化能力。生命科 学解决方案板块利润同比增长7.6%，成为核心增长引擎，而分析仪器板块利润则下滑11.2%。公司还推 ...

小核酸药物赛道再添重磅国际合作。 2月23日晚间，前沿生物（688221）公告，公司已于2月16日与跨国药巨头葛兰素史克（GSK）签署独家授权协议，将旗下两款小核酸（siRNA）在研产品 的全球权益授予GSK。 分工明确 权益清晰 根据公告，此次授权的两款产品中，一款候选药物已进入新药临床试验申请（IND）阶段，另一款处于临床前阶段。 根据协议，前沿生物将负责其中一款产品在中国的I期临床试验推进，以及另一款产品的IND支持性研究；GSK则将主导两款产品后续的全球临床开发、 注册申报及商业化工作。 根据协议，前沿生物将获得4000万美元首付款及1300万美元近期里程碑付款，并有望在后续开发、监管和商业化过程中获得最高9.5亿美元的里程碑付 款，交易总金额累计超过10亿美元。此外，前沿生物还将享有两款产品全球净销售额的分级特许权使用费。 前沿生物在公告中表示，此次合作不仅将为公司带来可观的现金流支持，助力核心研发投入与技术平台升级，也标志着其在小核酸药物领域的技术实力获 得国际认可。公司在此次合作中将借助GSK在全球临床开发与商业化方面的资源与经验，加速公司管线的国际化价值转化，并为后续推进产品商业化、拓 展全球 ...

Core Insights - Redmile Group acquired 4,415,514 shares of Nurix Therapeutics, valued at approximately $63.43 million, as disclosed in a SEC filing on February 17, 2026 [2][4] - The value of Redmile's position in Nurix increased by $119.55 million, reflecting both new purchases and stock price changes [2] - Nurix Therapeutics is focused on developing targeted therapies for cancer and immune disorders, leveraging partnerships with major pharmaceutical companies [6][8] Company Overview - As of February 17, 2026, Nurix Therapeutics had a market capitalization of $1.37 billion and a stock price of $15.64, which is down 6.52% over the past year [4][7] - The company reported a total revenue of $83.98 million for the trailing twelve months (TTM) but incurred a net loss of $264.46 million [4][9] - Nurix's cash and marketable securities stood at $592.9 million at the end of fiscal 2025, supported by a $250 million equity offering [9] Investment Implications - Despite recent stock performance trailing the broader market, Nurix's lead program, a BTK degrader, has shown promising Phase 1 data with an 83% objective response rate [7][9] - Redmile's investment in Nurix now constitutes 11.31% of its total assets under management (AUM), indicating a significant conviction in the company's potential [7][10] - The company is positioned to compete in the biopharmaceutical landscape with its innovative therapies targeting unmet needs in oncology and immunology [6][8]

Core Points - The Supreme Court ruled that tariffs imposed under the International Emergency Economic Powers Act (IEEPA) exceeded President Trump's authority, leading to the removal of a significant batch of tariffs [1][6] - Tariffs enacted under Section 232 of the Trade Expansion Act of 1962, aimed at protecting U.S. national security, remain in effect [2] Automotive Industry - Foreign vehicles and auto parts are still subject to a 25% tariff, which was implemented to encourage U.S. manufacturing [4] - Automakers are facing substantial financial impacts due to these tariffs, with Mercedes-Benz reporting a $1.2 billion hit to earnings in 2025 [5] - Ford anticipates a tariff bill similar to last year's $2 billion, while General Motors expects a $3.1 billion charge in 2025 and an additional $3 billion to $4 billion in 2026 [7] Furniture Industry - The furniture sector is affected by a 25% tariff on upholstered couches, kitchen cabinets, and vanities, which is set to increase to 50% in 2027 [11] - This industry is particularly sensitive to tariffs due to the high volume of imported goods [11] Steel and Aluminum Industry - Steel and aluminum imports continue to face a 50% tariff, impacting companies in home appliances, electronics, and beverage industries [13] Semiconductor Industry - A 25% tariff on certain semiconductors and chipmaking equipment remains in place, which took effect last month [14] Pharmaceutical Industry - While tariffs as high as 250% on pharmaceuticals have been avoided, there is potential for future tariffs under Section 232 if agreements with drugmakers are reversed [15][16] - Major pharmaceutical companies have agreed to lower drug prices to avoid tariffs for at least three years [16]

Sanofi (NASDAQ:SNY) is one of the Best Dip Stocks to Buy According to Hedge Funds. On February 17, Sanofi (NASDAQ:SNY) announced Manuela Buxo will replace Brian Foard as the Head of its Specialty Care Global Business Unit. Brian Foard, after serving for nearly 9 years, is leaving on February 28 to take on a leadership role elsewhere. ​Manuela Buxo will take over as the Head of Specialty Care Unit on March 1, 2026. She is currently the head of Sanofi’s (NASDAQ:SNY) Global Immunology Alliance Franchise. Fo ...

L’Oréal SA played a key role in the ouster last week of Sanofi SA Chief Executive Officer Paul Hudson and the choice of his successor, in what was a major corporate shakeup for the French pharmaceutical company. https://t.co/EIU9A7PMZW ...

Core Insights - The biotech industry experienced significant developments this week, including FDA approvals, clinical trial results, and licensing agreements, indicating a dynamic landscape for investment opportunities and advancements in healthcare [1]. FDA Approvals & Rejections - NRx Pharmaceuticals is on track for FDA approval of NRX-100, with existing clinical data and real-world evidence from over 65,000 patients potentially supporting a New Drug Application (NDA) under Fast Track Designation [2][3]. - Kane Biotech received FDA clearance for its Revyve Antimicrobial Skin and Wound Cleanser, which targets wound bacteria and biofilms, with plans for manufacturing scale-up in 2026 [4][5]. - Johnson & Johnson's RYBREVANT FASPRO received FDA approval for a simplified monthly dosing schedule, enhancing treatment options for patients with advanced non-small cell lung cancer [6][7]. - Spruce Biosciences reported positive feedback from FDA Type B meetings for its enzyme replacement therapy for Sanfilippo syndrome type B, with a targeted BLA filing in Q4 2026 [8][9]. - Moderna's seasonal influenza vaccine submission (mRNA-1010) is under FDA review, with a PDUFA date set for August 5, 2026, aiming for availability in the 2026/2027 flu season [10][11]. - Disc Medicine received a Complete Response Letter (CRL) for its NDA for Biopertin in erythropoietic protoporphyria, citing insufficient correlation with sunlight exposure endpoints [13][14]. - AbbVie and Genentech's combination regimen of VENCLEXTA and Acalabrutinib for chronic lymphocytic leukemia (CLL) received FDA approval, showing a 35% reduction in disease progression risk compared to standard treatment [15][16]. Deals - Theriva Biologics entered an exclusive licensing agreement with Rasayana Therapeutics for SYN-020, receiving a $3 million upfront payment and potential milestone payments totaling up to $38 million [17][18]. - Sensei Biotherapeutics acquired Faeth Therapeutics, expanding its oncology portfolio with the investigational asset PIKTOR, and announced a concurrent private placement of $200 million to advance clinical milestones [19][20]. Clinical Trials - Breakthroughs - Eli Lilly's Taltz and Zepbound combination therapy showed positive results in a Phase 3 trial for plaque psoriasis and obesity, achieving superior outcomes compared to Taltz alone [21][22]. - Zealand Pharma reported positive Phase 1a results for ZP9830, a Kv1.3 channel blocker, demonstrating safety and tolerability in healthy volunteers [23][24]. - Novartis' Remibrutinib met primary endpoints in a Phase 3 trial for chronic inducible urticaria, showing significant response rates compared to placebo [26][27]. - Ocular Therapeutix's AXPAXLI demonstrated superiority over aflibercept in a Phase 3 trial for wet age-related macular degeneration, although stock prices fell due to investor disappointment [28][29]. - Rallybio's RLYB116 Phase 1 study showed promising results for immune platelet transfusion refractoriness, with plans for a Phase 2 trial in 2026 [31][32]. - Teva and Sanofi's Duvakitug Phase 2b trial demonstrated durable efficacy in ulcerative colitis and Crohn's disease, reinforcing the rationale for ongoing Phase 3 programs [35][36]. - Genentech's Gazyva met primary endpoints in a Phase III study for primary membranous nephropathy, showing significant remission rates compared to tacrolimus [38][39].

Core Viewpoint - Ocular Therapeutix Inc. shares declined following the announcement of Axpaxli treatment data for wet age-related macular degeneration, which did not meet investor expectations [1][2]. Group 1: Trial Results - The SOL-1 Phase 3 superiority trial showed that 74.1% of subjects treated with Axpaxli maintained vision at Week 36, compared to 65.9% in the aflibercept arm, resulting in a risk difference of 17.5% (p=0.0006) [4]. - At Week 52, 65.9% of subjects in the Axpaxli arm maintained vision, compared to 44.2% in the aflibercept arm, with a risk difference of 21.1% [6]. - The trial indicated that 80.6% of subjects in the Axpaxli arm were rescue-free at Week 24, significantly outperforming the aflibercept group [5]. Group 2: Commercial Outlook - The durability advantage of Axpaxli over the active control was smaller than anticipated, raising concerns about its commercial outlook in a market with established therapies [2]. - Ocular Therapeutix plans to submit a New Drug Application (NDA) based on the SOL-1 data, pending discussions with the U.S. FDA [8]. - If approved, Axpaxli could become the first tyrosine kinase inhibitor (TKI) commercialized for wet AMD, potentially holding a superiority label and best-in-disease durability [8]. Group 3: Acquisition Interest - Sanofi SA was reportedly bidding for Ocular Therapeutix, indicating potential interest in the company and its pipeline [7].